ATE528014T1 - Polypeptid mit modifizierten kunitz domains - Google Patents

Polypeptid mit modifizierten kunitz domains

Info

Publication number: ATE528014T1
Authority: AT; Austria
Prior art keywords: phe; cys; glu; ala; polypeptide
Prior art date: 2002-06-07

Application number

AT07023364T

Other languages

English (en)

Inventor

Robert C Ladner

Arthur Ley

Original Assignee

Dyax Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-06-07

Filing date

2003-06-06

Publication date

2011-10-15

2003-06-06 Application filed by Dyax Corp filed Critical Dyax Corp

2011-10-15 Application granted granted Critical

2011-10-15 Publication of ATE528014T1 publication Critical patent/ATE528014T1/de

Links

229920001184 polypeptide Polymers 0.000 title abstract 3
108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
150000001413 amino acids Chemical group 0.000 abstract 2
WQVFQXXBNHHPLX-ZKWXMUAHSA-N Ala-Ala-His Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O WQVFQXXBNHHPLX-ZKWXMUAHSA-N 0.000 abstract 1
BGDILZXXDJCKPF-CIUDSAMLSA-N Arg-Gln-Cys Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(O)=O BGDILZXXDJCKPF-CIUDSAMLSA-N 0.000 abstract 1
HUZGPXBILPMCHM-IHRRRGAJSA-N Asn-Arg-Phe Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O HUZGPXBILPMCHM-IHRRRGAJSA-N 0.000 abstract 1
FANQWNCPNFEPGZ-WHFBIAKZSA-N Asp-Asp-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O FANQWNCPNFEPGZ-WHFBIAKZSA-N 0.000 abstract 1
YWEHYKGJWHPGPY-XGEHTFHBSA-N Cys-Thr-Arg Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CS)N)O YWEHYKGJWHPGPY-XGEHTFHBSA-N 0.000 abstract 1
NUSWUSKZRCGFEX-FXQIFTODSA-N Glu-Glu-Cys Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CS)C(O)=O NUSWUSKZRCGFEX-FXQIFTODSA-N 0.000 abstract 1
YLJHCWNDBKKOEB-IHRRRGAJSA-N Glu-Glu-Phe Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O YLJHCWNDBKKOEB-IHRRRGAJSA-N 0.000 abstract 1
IDEODOAVGCMUQV-GUBZILKMSA-N Glu-Ser-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O IDEODOAVGCMUQV-GUBZILKMSA-N 0.000 abstract 1
XXGQRGQPGFYECI-WDSKDSINSA-N Gly-Cys-Glu Chemical compound NCC(=O)N[C@@H](CS)C(=O)N[C@H](C(O)=O)CCC(O)=O XXGQRGQPGFYECI-WDSKDSINSA-N 0.000 abstract 1
VEPIBPGLTLPBDW-URLPEUOOSA-N Ile-Phe-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N VEPIBPGLTLPBDW-URLPEUOOSA-N 0.000 abstract 1
PRTZQMBYUZFSFA-XEGUGMAKSA-N Ile-Tyr-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)NCC(=O)O)N PRTZQMBYUZFSFA-XEGUGMAKSA-N 0.000 abstract 1
102000001399 Kallikrein Human genes 0.000 abstract 1
108060005987 Kallikrein Proteins 0.000 abstract 1
KJIXWRWPOCKYLD-IHRRRGAJSA-N Lys-Lys-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)N KJIXWRWPOCKYLD-IHRRRGAJSA-N 0.000 abstract 1
BKIFWLQFOOKUCA-DCAQKATOSA-N Met-His-Ser Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CO)C(=O)O)N BKIFWLQFOOKUCA-DCAQKATOSA-N 0.000 abstract 1
KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 abstract 1
UEHNWRNADDPYNK-DLOVCJGASA-N Phe-Cys-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC1=CC=CC=C1)N UEHNWRNADDPYNK-DLOVCJGASA-N 0.000 abstract 1
DNAXXTQSTKOHFO-QEJZJMRPSA-N Phe-Lys-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CC=CC=C1 DNAXXTQSTKOHFO-QEJZJMRPSA-N 0.000 abstract 1
OWSLLRKCHLTUND-BZSNNMDCSA-N Phe-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC(=O)N)C(=O)O)N OWSLLRKCHLTUND-BZSNNMDCSA-N 0.000 abstract 1
NUZHSNLQJDYSRW-BZSNNMDCSA-N Pro-Arg-Trp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O NUZHSNLQJDYSRW-BZSNNMDCSA-N 0.000 abstract 1
AIZVVCMAFRREQS-GUBZILKMSA-N Pro-Cys-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O AIZVVCMAFRREQS-GUBZILKMSA-N 0.000 abstract 1
108010041407 alanylaspartic acid Proteins 0.000 abstract 1
108010084264 glycyl-glycyl-cysteine Proteins 0.000 abstract 1
108010012581 phenylalanylglutamate Proteins 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
General Engineering & Computer Science (AREA)
Dermatology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Hematology (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)

AT07023364T 2002-06-07 2003-06-06 Polypeptid mit modifizierten kunitz domains ATE528014T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US38723902P	2002-06-07	2002-06-07
US40700302P	2002-08-28	2002-08-28

Publications (1)

Publication Number	Publication Date
ATE528014T1 true ATE528014T1 (de)	2011-10-15

Family

ID=29739936

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT07023364T ATE528014T1 (de)	2002-06-07	2003-06-06	Polypeptid mit modifizierten kunitz domains
AT03757339T ATE477020T1 (de)	2002-06-07	2003-06-06	Prevention und verringerung von ischemia

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AT03757339T ATE477020T1 (de)	2002-06-07	2003-06-06	Prevention und verringerung von ischemia

Country Status (12)

Country	Link
US (13)	US7064107B2 (de)
EP (4)	EP1531791B1 (de)
JP (3)	JP2005534647A (de)
AT (2)	ATE528014T1 (de)
AU (3)	AU2003243394B2 (de)
CA (1)	CA2488558C (de)
CY (1)	CY1112228T1 (de)
DE (1)	DE60333758D1 (de)
DK (4)	DK1941867T3 (de)
ES (4)	ES2528254T3 (de)
PT (4)	PT1531791E (de)
WO (1)	WO2003103475A2 (de)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6057287A (en)	1994-01-11	2000-05-02	Dyax Corp.	Kallikrein-binding "Kunitz domain" proteins and analogues thereof
PT1489097E (pt)	1994-01-11	2012-01-04	Dyax Corp	Inibidores de plasmina humana derivados de domínios kunitz e ácidos nucleicos codificando os mesmos
AU2001279203A1 (en)	2000-07-31	2002-02-13	Harman International Industries Inc.	Loudspeaker coil suspension system
US20050222023A1 (en) *	2002-02-07	2005-10-06	Hans-Peter Hauser	Albumin-fused kunitz domain peptides
US7153829B2 (en) *	2002-06-07	2006-12-26	Dyax Corp.	Kallikrein-inhibitor therapies
CA2488558C (en)	2002-06-07	2013-08-20	Dyax Corp.	Prevention and reduction of blood loss
ES2709103T3 (es) *	2002-08-28	2019-04-15	Dyax Corp	Métodos para conservar órganos y tejidos
US6989369B2 (en) *	2003-02-07	2006-01-24	Dyax Corp.	Kunitz domain peptides
DK1663281T3 (en) *	2003-08-29	2014-03-17	Dyax Corp	POLY-PEGYLED PROTEASE INHIBITORS
WO2005027834A2 (en) *	2003-09-12	2005-03-31	Z-Medica Corporation	Partially hydrated hemostatic agent
US20060177971A1 (en) *	2004-01-13	2006-08-10	Jsr Corporation	Anisotropically conductive connector, production process thereof and application product thereof
US7235530B2 (en) *	2004-09-27	2007-06-26	Dyax Corporation	Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
JP5118492B2 (ja) *	2004-12-23	2013-01-16	ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー	血栓の形成の防止および／または安定化の防止
US20060178609A1 (en)	2005-02-09	2006-08-10	Z-Medica, Llc	Devices and methods for the delivery of molecular sieve materials for the formation of blood clots
KR20070117589A (ko)	2005-02-15	2007-12-12	버지니아 커먼웰스 유니버시티	급성 지혈 및 급성 상처와 만성 궤양의 치료를 위한 광물기술
US9829494B2 (en)	2005-12-01	2017-11-28	Adrenomed Ag	Methods of treatment using ADM antibodies
CA2643693A1 (en) *	2006-03-10	2007-09-20	Dyax Corp.	Formulations for ecallantide
PL2374472T3 (pl) *	2006-03-16	2018-11-30	Dyax Corp.	Kompozycje i sposoby leczenia zaburzeń okulistycznych
HUE039108T2 (hu) *	2006-03-16	2018-12-28	Dyax Corp	Készítmények és eljárások szembetegségek kezelésére
US8938898B2 (en) *	2006-04-27	2015-01-27	Z-Medica, Llc	Devices for the identification of medical products
US7604819B2 (en)	2006-05-26	2009-10-20	Z-Medica Corporation	Clay-based hemostatic agents and devices for the delivery thereof
US8202532B2 (en) *	2006-05-26	2012-06-19	Z-Medica Corporation	Clay-based hemostatic agents and devices for the delivery thereof
US7968114B2 (en)	2006-05-26	2011-06-28	Z-Medica Corporation	Clay-based hemostatic agents and devices for the delivery thereof
US20080085300A1 (en) *	2006-10-06	2008-04-10	Z-Medica Corporation	Hemostatic compositions and method of manufacture
US9345457B2 (en)	2006-12-13	2016-05-24	Devicor Medical Products, Inc.	Presentation of biopsy sample by biopsy device
EP2195010A4 (de) *	2007-08-21	2012-03-14	Genzyme Corp	Behandlung mit kallikrein-inhibitoren
CA2695012A1 (en) *	2007-08-23	2009-02-26	Genzyme Corporation	Treatment with kallikrein inhibitors
US20090162406A1 (en) *	2007-09-05	2009-06-25	Z-Medica Corporation	Wound healing with zeolite-based hemostatic devices
US8637454B2 (en)	2009-01-06	2014-01-28	Dyax Corp.	Treatment of mucositis with kallikrein inhibitors
RS62853B1 (sr)	2010-01-06	2022-02-28	Takeda Pharmaceuticals Co	Proteini koji vezuju kalikrein plazme
EP2347778A1 (de)	2010-01-25	2011-07-27	ECP Entwicklungsgesellschaft mbH	Fluidpumpe mit einem radial komprimierbaren Rotor
US8858969B2 (en)	2010-09-22	2014-10-14	Z-Medica, Llc	Hemostatic compositions, devices, and methods
AU2012204202A1 (en)	2011-01-06	2013-07-11	Dyax Corp.	Plasma kallikrein binding proteins
CA2838984A1 (en)	2011-06-10	2012-12-13	Isis Pharmaceuticals, Inc.	Methods for modulating kallikrein (klkb1) expression
WO2013003808A1 (en)	2011-06-29	2013-01-03	Isis Pharmaceuticals, Inc.	Methods for modulating kallikrein (klkb1) expression
PL2594587T3 (pl)	2011-11-16	2014-11-28	Adrenomed Ag	Przeciwciało przeciwko adrenomedulinie (ADM) lub fragment przeciwciała anty-ADM lub szkielet białkowy niestanowiący Ig anty-ADM do zmniejszenia ryzyka śmierci u pacjenta cierpiącego na chorobę przewlekłą lub ostrą lub stan ostry
HRP20170427T1 (hr)	2011-11-16	2017-06-16	Sphingotec Gmbh	Testovi na adrenomedulin i postupci određivanja zrelog adrenomedulina
SG10201802054TA (en)	2011-11-16	2018-05-30	Adrenomed Ag	Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for regulating the fluid balance in a patient having a chronic or acute disease
NZ624873A (en)	2011-11-16	2016-07-29	Adrenomed Ag	Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition
KR102249078B1 (ko)	2011-11-16	2021-05-10	아드레노메드 아게	요법에 사용하기 위한 항-아드레노메둘린 (adm) 항체 또는 항-adm 항체 단편 또는 항-adm 비-ig 스캐폴드
ES2751492T3 (es)	2011-11-16	2020-03-31	Adrenomed Ag	Anticuerpo anti-adrenomedulina (ADM) o fragmento de anticuerpo anti-ADM o armazón no Ig anti-ADM para uso en la terapia de una enfermedad aguda o una afección aguda de un paciente para estabilizar la circulación
CN103308673B (zh)	2012-03-08	2017-05-31	思芬构技术有限公司	用于预测雌性对象中发生心血管事件的风险的方法
CN103308689B (zh)	2012-03-08	2017-04-12	思芬构技术有限公司	用于预测雌性对象中患上癌症的风险或诊断癌症的方法
CN103308670B (zh)	2012-03-08	2017-06-09	思芬构技术有限公司	用于预测对象患糖尿病和/或代谢综合征的风险的方法
WO2013191836A1 (en)	2012-06-22	2013-12-27	Z-Medica, Llc	Hemostatic devices
DK2904403T3 (en)	2012-10-02	2018-07-16	Sphingotec Gmbh	PROCEDURE FOR DIAGNOSTICATION OR MONITORING OF Kidney Function or Diagnosis of Kidney Function
RU2677895C2 (ru)	2013-01-08	2019-01-22	Сфинготек Гмбх	Уровни гормона роста натощак в качестве прогностического маркера сердечно-сосудистого риска
IL273688B2 (en)	2013-01-20	2024-12-01	Dyax Corp	Evaluation and treatment of bradykinin-mediated disorders
HRP20190528T1 (hr)	2013-01-20	2019-05-17	Dyax Corp.	PROCJENA, TESTOVI I LIJEČENJE POREMEĆAJA POSREDOVANIH S pKAL
SG10201800309SA (en)	2013-03-20	2018-02-27	Sphingotec Gmbh	Adrenomedullin to guide therapy of blood pressure decline
RU2712559C9 (ru)	2013-08-28	2020-10-08	Ионис Фармасьютикалз, Инк.	Модуляция экспрессии прекалликреина (пкк)
WO2015061182A1 (en)	2013-10-21	2015-04-30	Dyax Corp.	Diagnosis and treatment of autoimmune diseases
EP3060582B1 (de)	2013-10-21	2020-09-23	Dyax Corp.	Assays zur bestimmung von plasmakallikreinsystem-biomarkern
PT3096798T (pt)	2014-01-21	2021-02-25	Dyax Corp	Proteínas de ligação à calicreína plasmática e seus usos no tratamento de angioedema hereditário
AU2015235967B2 (en)	2014-03-27	2020-10-22	Takeda Pharmaceutical Company Limited	Compositions and methods for treatment of diabetic macular edema
HUE052709T2 (hu)	2014-05-01	2021-05-28	Ionis Pharmaceuticals Inc	Módosított antiszensz oligonukleotidok konjugátumai és azok alkalmazása PKK expressziójának módosítására
EP3002589A1 (de)	2014-10-01	2016-04-06	sphingotec GmbH	Verfahren zur stratifizierung einer frau zur hormonersatztherapie
IL305207A (en)	2015-03-30	2023-10-01	Takeda Pharmaceuticals Co	Plasma kallikrein inhibitors and their uses to prevent the outbreak of hereditary angioedema
WO2016170023A1 (en)	2015-04-24	2016-10-27	Sphingotec Gmbh	A method for predicting the risk of incidence of chronic kidney disease
EP3839514B1 (de)	2015-10-19	2023-12-13	Takeda Pharmaceutical Company Limited	Immunoassay zum nachweis von gespaltenem hochmolekularem kininogen
CN116077648A (zh)	2015-12-11	2023-05-09	武田药品工业株式会社	血浆激肽释放酶抑制剂及其治疗遗传性血管性水肿发作的用途
CH713803B1 (de)	2016-04-21	2023-08-15	4TEEN4 Pharmaceuticals GmbH	Verfahren zur Diagnose durch Bestimmung von DPP3, Hemmer der Aktivität von DPP3 und Zusammensetzung mit einem Hemmer.
EP3474887A1 (de)	2016-06-27	2019-05-01	AiCuris Anti-infective Cures GmbH	Hcmv-eingangsinhibitoren
JP7191813B2 (ja)	2016-07-08	2022-12-19	シュピーンゴテックゲゼルシャフトミットベシュレンクテルハフツング	急性心不全に罹患している対象におけるうっ血を評価するためのアドレノメデュリン
KR20250073510A (ko)	2016-09-16	2025-05-27	다케다 파머수티컬 컴패니 리미티드	접촉 활성화 시스템과 연관된 질환을 위한 단백질 바이오마커
JP7319916B2 (ja)	2016-09-16	2023-08-02	武田薬品工業株式会社	遺伝性血管性浮腫のｒｎａバイオマーカー
IL314752A (en)	2016-09-16	2024-10-01	Takeda Pharmaceuticals Co	Metabolite biomarkers for diseases associated with the contact activation system
EP3309550A1 (de)	2016-10-12	2018-04-18	sphingotec GmbH	Verfahren zum nachweis von apolipoprotein e4
MX2019007107A (es)	2016-12-16	2019-10-21	Adrenomed Ag	Anticuerpo anti-adrenomedulina (adm) o fragmento de anticuerpo anti-adm o supercontigo sin ig anti-adm para su uso en intervencion y terapia de congestion en un paciente con necesidad del mismo.
EP3339324A1 (de)	2016-12-22	2018-06-27	sphingotec GmbH	Anti-adrenomedullin (adm)-antikörper oder anti-adm antikörperfragment oder anti-adm-nicht-ig-gerüst zur verwendung in einer intervention und therapie von verstopfung bei einem darauf angewiesenen patienten
BR112019024966A2 (pt)	2017-05-30	2020-06-23	Sphingotec Gmbh	Método para diagnosticar ou monitorar a função renal ou diagnosticar a disfunção renal
WO2019057992A2 (en)	2017-09-25	2019-03-28	Adrenomed Ag	ANTI-ADRENOMEDULIN (ADM) BINDER FOR USE IN TREATING OR PREVENTING THE SYMPTOMS OF A DISEASE
BR112020005682A2 (pt)	2017-10-18	2020-10-20	Adrenomed Ag	monitoração de terapia sob tratamento com um aglutinante de antiadrenomedulina (adm)
EP3701266A1 (de)	2017-10-24	2020-09-02	sphingotec GmbH	Selenoprotein zur vorhersage eines ersten kardiovaskulären ereignisses
MY202502A (en)	2017-10-25	2024-05-01	4TEEN4 Pharmaceuticals GmbH	Dpp3 binder directed to and binding to specific dpp3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress
EP3569614A1 (de)	2018-05-18	2019-11-20	Julius-Maximilians-Universität Würzburg	Verbindungen und verfahren zur immobilisierung von myostatin-inhibitoren auf der extrazellulären matrix durch transglutaminase
EP3586865A1 (de)	2018-06-21	2020-01-01	Charité - Universitätsmedizin Berlin	Ergänzende anaphylatoxinbindemittel und deren verwendung in der behandlung einer person mit okularer wunde und/oder fibrose
AU2019328324B2 (en)	2018-08-30	2025-06-19	Takeda Pharmaceutical Company Limited	Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
AU2019408553A1 (en)	2018-12-20	2021-06-17	Sphingotec Gmbh	Selenoprotein P in heart failure
WO2020128039A2 (en)	2018-12-21	2020-06-25	4TEEN4 Pharmaceuticals GmbH	Therapy guidance and/or therapy monitoring for a treatment with angiotensin-receptor-agonist and/or a precursor thereof
EP3938404A1 (de)	2019-03-14	2022-01-19	Takeda Pharmaceutical Company Limited	Plasma-kallikrein-inhibitoren und verwendungen davon zur behandlung von hereditärem angioödem
EP4014049A1 (de)	2019-08-15	2022-06-22	sphingotec GmbH	Verfahren zur diagnose oder überwachung der nierenfunktion oder zur diagnose von nierenfunktionsstörungen bei pädiatrischen patienten
RU2712629C1 (ru) *	2019-08-27	2020-01-30	Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Астраханский ГМУ Минздрава России)	Способ прогнозирования сердечно-сосудистых осложнений у больных ишемической болезнью сердца в сочетании с постинфарктной аневризмой левого желудочка
EP4552649A3 (de)	2019-08-30	2025-06-25	4TEEN4 Pharmaceuticals GmbH	Therapieführung und/oder therapieüberwachung zur behandlung von schock
MX2022008649A (es)	2020-01-13	2022-09-23	Takeda Pharmaceuticals Co	Inhibidores de calicreina plasmatica y sus usos para tratar episodios de angioedema hereditario pediatrico.
EP3871689A1 (de)	2020-02-26	2021-09-01	sphingotec GmbH	Anti-adm-antikörper, die an den freien n-terminus binden, für einen beschleunigten übergang von adm-gly zu bio-adm bei patienten mit einem adm-gly/bio-adm-verhältnis über einem schwellenwert und kombination mit vitamin c
AU2021228207A1 (en)	2020-02-27	2022-10-20	4TEEN4 Pharmaceuticals GmbH	DPP3 for therapy guidance, monitoring and stratification of nt-ADM antibodies in patients with shock
WO2021170880A2 (en)	2020-02-27	2021-09-02	Adrenomed Ag	Anti-adrenomedullin (adm) binder for use in therapy of patients in shock
CA3168978A1 (en)	2020-02-27	2021-09-02	Andreas Bergmann	Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock
EP3922993A1 (de)	2020-06-12	2021-12-15	4TEEN4 Pharmaceuticals GmbH	Dpp3 bei patienten, die mit coronavirus infiziert sind
EP4121772A1 (de)	2020-03-16	2023-01-25	sphingotec GmbH	Proadrenomedullin oder fragment davon bei patienten mit coronavirusinfektion und behandlungen mit bindemittel gegen adrenomedullin
MX2022011583A (es)	2020-03-16	2022-10-18	4TEEN4 Pharmaceuticals GmbH	Dpp3 en pacientes infectados con coronavirus.
EP4126219A2 (de)	2020-04-04	2023-02-08	Takeda Pharmaceutical Company Limited	Plasmakallikreinhemmer und verwendungen davon zur behandlung von akutem atemnotsyndrom
EP4023218A1 (de)	2020-12-02	2022-07-06	S-Form Pharma	Kombinationstherapie für patienten mit akuter und/oder anhaltender dyspnoe
WO2022263648A1 (en)	2021-06-18	2022-12-22	Sphingotec Gmbh	A method for predicting sepsis and septic shock
KR20240041912A (ko)	2021-06-29	2024-04-01	베리솔 게엠베하	체액내 셀레늄 결핍을 식별하기 위한 복합 바이오마커
EP4548103A2 (de)	2022-06-30	2025-05-07	Takeda Pharmaceutical Company Limited	Proteinbiomarker zur behandlung von lanadlumab
EP4562430A1 (de)	2022-07-29	2025-06-04	4TEEN4 Pharmaceuticals GmbH	Vorhersage einer erhöhung von dpp3 bei einem patienten mit septischem schock
IL318667A (en)	2022-07-29	2025-03-01	Adrenomed Ag	Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock
JP2025541138A (ja)	2022-12-15	2025-12-18	４ティーン４ファーマシューティカルズゲゼルシャフトミットベシュレンクテルハフツング	重篤な患者における肺機能の改善のためのｄｐｐ３阻害剤
CN120731367A (zh)	2023-03-17	2025-09-30	Pam治疗诊断有限公司	肽基甘氨酸α-酰胺化单加氧酶（PAM）的测定方法及其诊断用途
EP4687942A1 (de)	2023-03-29	2026-02-11	4TEEN4 Pharmaceuticals GmbH	Dpp3-hemmer für herzmuskelschutz und prävention von myokardläsionen bei kritisch kranken patienten mit blutdruckabfall
WO2025068313A1 (en)	2023-09-25	2025-04-03	Sphingotec Gmbh	A method for early diagnosis, early prediction, monitoring or prediction of severity of reduced graft function in a kidney transplantation patient
WO2025229075A1 (en)	2024-05-03	2025-11-06	Sphingotec Gmbh	A method for the specific determination of proenkephalin fragment 119-159
WO2025248139A1 (en)	2024-05-31	2025-12-04	4TEEN4 Pharmaceuticals GmbH	Use of adrenomedullin or fragments thereof in the treatment of a patient in need thereof
EP4675277A1 (de)	2024-07-05	2026-01-07	Predemtec AG	Verfahren zur diagnose von morbus alzheimer oder zur bestimmung des risikos des leidens an morbus alzheimer
WO2026046968A1 (en)	2024-08-26	2026-03-05	4TEEN4 Pharmaceuticals GmbH	Dpp3 binders for the treatment of endothelial dysfunction
WO2026046978A1 (en)	2024-08-26	2026-03-05	Pam Theragnostics Gmbh	Anti-adm antibodies, anti-adm antibody fragment or anti-adm non-ig scaffold for therapy or prevention of immune effector cell therapy side effects

Family Cites Families (211)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AT275583B (de)	1964-03-04	1969-10-27	Plasser Bahnbaumasch Franz	Profilfreie Maschine zum Reinigen des Eisenbahnbettungsschotters
BR6915369D0 (pt)	1969-02-27	1973-03-13	Bayer Ag	Emprego de inibidores biologicos de proteases para conservacao de orgaos tecidos e alimentos
US3691016A (en)	1970-04-17	1972-09-12	Monsanto Co	Process for the preparation of insoluble enzymes
CA1023287A (en)	1972-12-08	1977-12-27	Boehringer Mannheim G.M.B.H.	Process for the preparation of carrier-bound proteins
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
DE2619246A1 (de)	1976-04-30	1977-11-10	Bayer Ag	Desamino-derivate des kallikrein- trypsin-inhibitors, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
US4195128A (en)	1976-05-03	1980-03-25	Bayer Aktiengesellschaft	Polymeric carrier bound ligands
DE2654124A1 (de)	1976-11-29	1978-06-01	Bayer Ag	Derivate des trypsin-kallikrein-inhibitors aus rinderorganen (bpti) mit proteasenhemmwirkung und antiphlogistischer wirkung, ihre herstellung und ihre verwendung als arzneimittel
US4330440A (en)	1977-02-08	1982-05-18	Development Finance Corporation Of New Zealand	Activated matrix and method of activation
CA1093991A (en)	1977-02-17	1981-01-20	Hideo Hirohara	Enzyme immobilization with pullulan gel
CA1113397A (en) *	1977-11-09	1981-12-01	Peter F.R. Lunn	Aqueous persulphate and percarbonate composition for bleaching hair
US4229537A (en)	1978-02-09	1980-10-21	New York University	Preparation of trichloro-s-triazine activated supports for coupling ligands
AT359653B (de)	1979-02-15	1980-11-25	Immuno Ag	Verfahren zur herstellung eines gewebekleb- stoffes
US4299537A (en) *	1979-06-19	1981-11-10	Evans Frederick C	Interlinked variable-pitch blades for windmills and turbines
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en)	1980-02-25	1993-01-12	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en)	1980-02-25	1987-01-06	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4447233A (en)	1981-04-10	1984-05-08	Parker-Hannifin Corporation	Medication infusion pump
US4447224A (en)	1982-09-20	1984-05-08	Infusaid Corporation	Variable flow implantable infusion apparatus
AU560584B2 (en)	1983-07-28	1987-04-09	Bayer Aktiengesellschaft	Homologues of aprotinin
US4657893A (en)	1984-05-09	1987-04-14	Syntex (U.S.A.) Inc.	4H-3,1-benzoxazin-4-ones and related compounds and use as enzyme inhibitors
US4845242A (en)	1987-04-28	1989-07-04	Georgia Tech Research Corporation	Isocoumarins with basic substituents as serine proteases inhibitors, anticoagulants and anti-inflammatory agents
US4609725A (en)	1984-10-09	1986-09-02	Merck & Co., Inc.	Cardiac atrial peptides
US4931385A (en) *	1985-06-24	1990-06-05	Hygeia Sciences, Incorporated	Enzyme immunoassays and immunologic reagents
US5444156A (en) *	1985-07-12	1995-08-22	Temple University-Of The Commonwealth System Of Higher Education	Monoclonal antibodies to human plasma prekallikrein
JPH0623113B2 (ja)	1986-01-31	1994-03-30	浩前田	癌性胸・腹水貯留抑制剤
EP0255011A3 (de)	1986-07-29	1988-11-23	Miles Inc.	Menschliches Inter-alpha-trypsin-Inhibitorgen
US5260203A (en)	1986-09-02	1993-11-09	Enzon, Inc.	Single polypeptide chain binding molecules
US4881175A (en)	1986-09-02	1989-11-14	Genex Corporation	Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5187153A (en)	1986-11-17	1993-02-16	Scios Nova Inc.	Methods of treatment using Alzheimer's amyloid polypeptide derivatives
EP0332640A1 (de)	1986-11-17	1989-09-20	California Biotechnology, Inc.	Rekombinantes alzheimer-amyloidprotein
EP0285123A3 (de)	1987-04-03	1989-02-01	Stabra AG	Verfahren zur vollständigen Mutagenese von Nucleinsäuren
US4966852A (en)	1987-07-23	1990-10-30	Monsanto Company	DNA clone of human tissue factor inhibitor
US5106833A (en)	1987-07-23	1992-04-21	Washington University	Coagulation inhibitors
IL87172A (en)	1987-07-23	1994-12-29	Univ Washington	Method of isolating highly purified tissue factor inhibitor
GB2208511A (en)	1987-08-07	1989-04-05	Bayer Ag	Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology
DK225488D0 (da)	1988-04-26	1988-04-26	Novo Industri As	Polypeptid
IL87171A (en)	1987-11-23	1995-08-31	Monsanto Co	cDNA of human tissue factor inhibitor
EP1541682A3 (de)	1988-09-02	2005-07-06	Dyax Corp.	Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
US5663143A (en)	1988-09-02	1997-09-02	Dyax Corp.	Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US7078383B2 (en)	1988-09-02	2006-07-18	Dyax Corp.	ITI-D1 Kunitz domain mutants as HNE inhibitors
US5372933A (en) *	1988-10-03	1994-12-13	The Scripps Research Institute	Polypeptides that mimic receptor-induced binding sites, and methods of using same
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
DK0401508T3 (da)	1989-05-13	1995-05-15	Bayer Ag	Proteaseinhibitorer, fremgangsmåde til deres fremstilling samt lægemidler med indhold deraf
DK408089D0 (da)	1989-08-18	1989-08-18	Novo Nordisk As	Proteiner
US5378614A (en)	1989-08-18	1995-01-03	Novo Nordisk A/S	Vector and method for making tissue factor pathway inhibitor (TFPI) analogues in yeast
US5278285A (en)	1990-02-01	1994-01-11	Bayer Aktiengesellschaft	Variant of Kunitz-type inhibitor derived from the α3-chain of human type VI collagen produced by recombinant DNA technology
US5583107A (en)	1990-09-04	1996-12-10	Cor Therapeutics, Inc.	Agents affecting thrombosis and hemostasis
US5278144A (en)	1990-09-04	1994-01-11	Cor Therapeutics, Inc.	Antithrombosis agents
IL99585A0 (en)	1990-10-01	1992-08-18	Novo Nordisk As	Aprotinin analogues,their production and pharmaceutical compositions containing them
AU641568B2 (en)	1990-11-13	1993-09-23	Mochida Pharmaceutical Co., Ltd.	Polypeptide,DNA fragment encoding the same and process for producing the same, and enzyme inhibition process, drug composition and methods of treating using the same
US20030223977A1 (en)	1991-03-01	2003-12-04	Ley Arthur Charles	Kunitz domain mutants as cathepsin G inhibitors
US5166133A (en)	1991-04-17	1992-11-24	Cetus Corporation	Method for inhibing adhesion of white blood cells to endothelial cells
EP0940468A1 (de)	1991-06-14	1999-09-08	Genentech, Inc.	Änderliches Gebiet einer humanisierter Antikörper
WO1993009233A2 (en)	1991-10-31	1993-05-13	The Salk Institute Biotechnology/Industrial Associates Inc.	Recombinant amyloid precursor protein inhibitor domain and treatment of various disease states
IL104324A0 (en)	1992-01-07	1993-05-13	Novo Nordisk As	Variant of human kunitz-type protease inhibitor
IL104325A (en)	1992-01-07	2000-10-31	Novo Nordisk As	Variants of human kunitz-type protease inhibitor domain II of tissue factor pathway inhibitor (TFPI) pharmaceutical compositions containing them a DNA construct encoding them their expression vectors a cell containing said DNA constructs and methods for the production of all the above
IL104327A0 (en)	1992-01-07	1993-05-13	Novo Nordisk As	Variant of human kunitz-type protease inhibitor
IL104326A0 (en)	1992-01-07	1993-05-13	Novo Nordisk As	Variant of human kunitz-type protease inhibitor
IL104314A0 (en)	1992-01-07	1993-05-13	Novo Nordisk As	Human kunitz-type protease inhibitor and variants thereof,their production and pharmaceutical compositions containing them
US5212091A (en)	1992-03-02	1993-05-18	Monsanto Company	Method of producing tissue factor pathway inhibitor
US6063764A (en)	1992-06-01	2000-05-16	Washington University & Chiron Corp.	Method for using lipoprotein associated coagulation inhibitor to treat sepsis
EP0651766A4 (de) *	1992-07-13	1996-07-31	Corvas Int Inc	INHIBITOREN VON FAKTOR Xa, DIE SICH VOM INHIBITOR DES PANKREATISCHEN TRYPSON AUS RIND ABLEITEN.
US5436153A (en) *	1992-12-02	1995-07-25	Sprecher; Cindy A.	Human amyloid protein precursor homolog and Kunitz-type inhibitor
AU5684594A (en)	1992-12-02	1994-06-22	Novo Nordisk A/S	Novel human amyloid protein precursor homologue and kunitz-type inhibitors
US5426224A (en)	1993-03-18	1995-06-20	The University Of North Carolina At Chapel Hill	Mammalian DNA topoisomerase II inhibitor and method
JP3929484B2 (ja) *	1993-09-14	2007-06-13	ジェネンテック・インコーポレーテッド	エコチンおよびその同族体を含む医薬的組成物
US5455338A (en)	1993-11-05	1995-10-03	Zymogenetics, Inc.	DNA encoding novel human kunitz-type inhibitors and methods relating thereto
US5951974A (en)	1993-11-10	1999-09-14	Enzon, Inc.	Interferon polymer conjugates
US5446090A (en)	1993-11-12	1995-08-29	Shearwater Polymers, Inc.	Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5759548A (en)	1993-11-30	1998-06-02	Lxr Biotechnology Inc.	Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
US5827690A (en)	1993-12-20	1998-10-27	Genzyme Transgenics Corporatiion	Transgenic production of antibodies in milk
US6057287A (en)	1994-01-11	2000-05-02	Dyax Corp.	Kallikrein-binding "Kunitz domain" proteins and analogues thereof
PT739355E (pt) *	1994-01-11	2005-01-31	Dyax Corp	Proteinas de 'dominio de kunitz' inibidoras de calicreina e seus analogos
PT1489097E (pt)	1994-01-11	2012-01-04	Dyax Corp	Inibidores de plasmina humana derivados de domínios kunitz e ácidos nucleicos codificando os mesmos
US5795954A (en) *	1994-03-04	1998-08-18	Genentech, Inc.	Factor VIIa inhibitors from Kunitz domain proteins
HU221311B1 (en)	1994-06-02	2002-09-28	Merrell Pharma Inc	Perfluoroalkyl tripeptides inhibitors of elastase, pharmaceutical compositions comprising thereof and their use
US5589359A (en)	1994-08-05	1996-12-31	Chiron Corporation	Chimeric proteins
JP3779728B2 (ja)	1994-08-05	2006-05-31	カイロンコーポレイション	組織因子活性インヒビターの産生
US5648331A (en)	1994-08-26	1997-07-15	G.D. Searle & Co.	Method of inhibiting tissue ischemia and reperfusion injury
ES2276396T3 (es) *	1994-10-18	2007-06-16	Dendreon Corporation	Proteinas anticoagulantes e inhibidores de la serina proteasa extraidos de nematodos.
US6159938A (en) *	1994-11-21	2000-12-12	Cortech, Inc.	Serine protease inhibitors comprising α-keto heterocycles
JPH10510540A (ja) *	1994-12-12	1998-10-13	オメロスメディカルシステムズ，インコーポレーテッド	灌注用溶液並びに疼痛、炎症及びけいれんの抑制法
MX9703988A (es) *	1994-12-12	1998-02-28	Omeros Med Sys Inc	SOLUCIaN Y MÉTODO DE IRRIGACIaN PARA LA INHIBICIaN DEL DOLOR, LA INFLAMACIaN Y ES ESPASMO.
US5914316A (en)	1994-12-16	1999-06-22	Washington University	Method of inhibiting intimal hyperplasia
US5932462A (en)	1995-01-10	1999-08-03	Shearwater Polymers, Inc.	Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
ATE251141T1 (de) *	1995-03-10	2003-10-15	Berlex Lab	Benzamidin-derivate, deren herstellung und deren verwendung als anti-koagulantien
US5695760A (en)	1995-04-24	1997-12-09	Boehringer Inglehiem Pharmaceuticals, Inc.	Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation
US5804376A (en)	1995-05-02	1998-09-08	Incyte Pharmaceuticals, Inc.	Pancreas-derived serpin
ZA963619B (en) *	1995-05-08	1996-11-22	Scios Inc	Protease inhibitor peptides
WO1996035788A2 (en)	1995-05-08	1996-11-14	Scios, Inc.	Kunitz type protease inhibitors
US5780265A (en) *	1995-06-05	1998-07-14	Genentech, Inc.	Kunitz type plasma kallikrein inhibitors
US5786328A (en) *	1995-06-05	1998-07-28	Genentech, Inc.	Use of kunitz type plasma kallikrein inhibitors
US6242414B1 (en)	1995-06-07	2001-06-05	Chiron Corporation	Regulation of cytokine synthesis and release
US6126933A (en)	1995-06-27	2000-10-03	Genetics Institute	Methods of treating inflammatory bowel diseases by administering IL-11
US5672662A (en)	1995-07-07	1997-09-30	Shearwater Polymers, Inc.	Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
JPH0959838A (ja)	1995-08-24	1997-03-04	Kuraray Co Ltd	紡績糸
JPH11512439A (ja)	1995-09-14	1999-10-26	エルエックスアールバイオテクノロジーインコーポレイテッド	リン脂質の混合物を含む抗アポトーシス活性を有する組成物
KR19990063648A (ko)	1995-09-21	1999-07-26	프레드한 아룬디프 에스	글루타민산 데카복실라제에 대한 항체와 폴리(에틸렌 글리콜)공액물을 섬세포에 제공하는 방법
US5824870A (en)	1995-11-06	1998-10-20	Baszczynski; Chris	Commercial production of aprotinin in plants
US5736364A (en)	1995-12-04	1998-04-07	Genentech, Inc.	Factor viia inhibitors
AU716923B2 (en)	1996-03-11	2000-03-09	Aerovance, Inc.	Human bikunin
US6013763A (en) *	1996-06-04	2000-01-11	Genentech, Inc.	Peptide variants of protein A
JP3657700B2 (ja) *	1996-06-18	2005-06-08	新日本石油化学株式会社	カサ高性不織布の製造方法
US5869637A (en)	1996-07-22	1999-02-09	Incyte Pharmaceuticals, Inc.	Human Kallikrein
US6214966B1 (en)	1996-09-26	2001-04-10	Shearwater Corporation	Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US6255455B1 (en)	1996-10-11	2001-07-03	The Trustees Of The University Of Pennsylvania	Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
US6258351B1 (en)	1996-11-06	2001-07-10	Shearwater Corporation	Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels
EP1005551A2 (de)	1997-01-31	2000-06-07	Human Genome Sciences, Inc.	Inhibitor 3 des gewebefaktor-weges.
US5786238A (en) *	1997-02-13	1998-07-28	Generyal Dynamics Information Systems, Inc.	Laminated multilayer substrates
US5962300A (en)	1997-03-26	1999-10-05	Incyte Pharmaceuticals, Inc.	Human kallikrein
US5990237A (en)	1997-05-21	1999-11-23	Shearwater Polymers, Inc.	Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
DE69833755T2 (de)	1997-05-21	2006-12-28	Biovation Ltd.	Verfahren zur herstellung von nicht-immunogenen proteinen
JP2003525845A (ja)	1997-10-28	2003-09-02	ヴィヴァス・インコーポレイテッド	勃起機能不全の処置のためのホスホジエステラーゼインヒビターの局所投与
JP3786832B2 (ja)	1998-01-07	2006-06-14	デビオルシェルシュファルマシュティークソシエテアノニム	分解性のヘテロ二官能性ポリ（エチレングリコール）アクリレート及びそれから誘導されるゲル及び複合体
ATE268609T1 (de)	1998-03-12	2004-06-15	Nektar Therapeutics Al Corp	Polyethylenglycolderivate mit benachbarten reaktiven gruppen
US6455639B1 (en)	1998-03-24	2002-09-24	Nof Corporation	Oxirane derivative and process for the preparation thereof
US6017723A (en)	1998-03-27	2000-01-25	Long Island Jewish Medical Center	Method for isolating inhibitors of protease activity
US6001596A (en)	1998-05-07	1999-12-14	Incyte Pharmaceuticals, Inc.	Growth-associated protease inhibitor heavy chain precursor
US6087473A (en) *	1999-05-26	2000-07-11	Zymogenetics, Inc.	Kunitz domain polypeptide and materials and methods for making it
AU4229599A (en) *	1998-06-03	1999-12-20	Scios Inc.	Protease inhibitor peptides
CA2338665C (en)	1998-08-06	2011-01-18	Mountain View Pharmaceuticals, Inc.	Peg-urate oxidase conjugates and use thereof
US6783965B1 (en)	2000-02-10	2004-08-31	Mountain View Pharmaceuticals, Inc.	Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
CA2342072C (en)	1998-09-03	2005-01-11	Zymogenetics, Inc.	Kunitz domain polypeptide zkun6
US7067144B2 (en)	1998-10-20	2006-06-27	Omeros Corporation	Compositions and methods for systemic inhibition of cartilage degradation
US6565874B1 (en)	1998-10-28	2003-05-20	Atrix Laboratories	Polymeric delivery formulations of leuprolide with improved efficacy
AU2346900A (en)	1998-11-30	2000-06-19	Eli Lilly And Company	Erythropoietic compounds
AU776910B2 (en)	1998-12-08	2004-09-23	Merck Patent Gesellschaft Mit Beschrankter Haftung	Modifying protein immunogenicity
US20030012969A1 (en)	1999-04-06	2003-01-16	Clark Bert Thomas	Soluble membrane strengthened paper products
CN1349410A (zh)	1999-04-29	2002-05-15	诺沃挪第克公司	结合肝素的拮抗剂在缓激肽释放的抑制中的应用
US6605316B1 (en)	1999-07-31	2003-08-12	The Regents Of The University Of California	Structures and fabrication techniques for solid state electrochemical devices
US6180607B1 (en) *	1999-08-05	2001-01-30	Christopher Davies	Protein having proteinase inhibitor activity
NZ517202A (en)	1999-08-24	2004-05-28	Medarex Inc	Human CTLA-4 antibodies and their uses
IL149267A0 (en)	1999-11-12	2002-11-10	Maxygen Holdings Ltd	Interferon gamma conjugates
US6348558B1 (en)	1999-12-10	2002-02-19	Shearwater Corporation	Hydrolytically degradable polymers and hydrogels made therefrom
US6544760B2 (en)	1999-12-22	2003-04-08	Zymogenetics, Inc.	Kunitz domain polypeptide Zkun11
US6376604B2 (en)	1999-12-22	2002-04-23	Shearwater Corporation	Method for the preparation of 1-benzotriazolylcarbonate esters of poly(ethylene glycol)
US6413507B1 (en)	1999-12-23	2002-07-02	Shearwater Corporation	Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
US20020102703A1 (en)	1999-12-29	2002-08-01	Sheppard Paul O.	Kunitz domain polypeptide zkun10
GB9930882D0 (en) *	1999-12-30	2000-02-23	Nps Allelix Corp	GLP-2 formulations
AU2001249074A1 (en)	2000-03-13	2001-09-24	Eli Lilly And Company	Human hepatocyte growth factor activator inhibitor homologue
JP2003530838A (ja)	2000-04-12	2003-10-21	ヒューマンゲノムサイエンシズインコーポレイテッド	アルブミン融合タンパク質
CN1331213A (zh)	2000-06-30	2002-01-16	上海博德基因开发有限公司	一种新的多肽——人大蛋白10.01和编码这种多肽的多核苷酸
DE10034357C1 (de)	2000-07-14	2001-12-13	Elotherm Gmbh	Verfahren und Vorrichtung zum Härten von Flächen an Bauteilen
ATE549347T1 (de)	2000-09-08	2012-03-15	Schering Corp	Gene von säugetiere, und damit verbundene reagentien, methoden
DE60100500T2 (de)	2000-10-31	2004-04-15	Debiopharm S.A.	Suspension enthaltend ein epi-hne protein, verfahren zu ihrer herstellung, daraus hergestelltes trockenpulveraerosol, arzneimittelzusammensetzungen enthaltend diese suspension oder dieses aerosol und ihre verwendungen
WO2002061131A2 (en)	2000-12-04	2002-08-08	Bristol-Myers Squibb Company	Human single nucleotide polymorphisms
TW593427B (en)	2000-12-18	2004-06-21	Nektar Therapeutics Al Corp	Synthesis of high molecular weight non-peptidic polymer derivatives
US20020168323A1 (en)	2001-05-11	2002-11-14	Igor Gonda	Optimization of the molecular properties and formulation of proteins delivered by inhalation
HUP0400442A2 (hu)	2001-05-21	2005-03-29	Nektar Therapeutics	Kémiailag módosított inzulin pulmonáris beadása és eljárás az előállítására
US20040152633A1 (en)	2001-05-31	2004-08-05	Jorgensen Marianne Ulrich	Kunitz-type sequences and polypeptides
EP1406652A2 (de)	2001-07-10	2004-04-14	Omnio AB	Neue arzneimittelziele für arthritis
JP4287269B2 (ja)	2001-07-10	2009-07-01	日本電産サンキョー株式会社	バルブ駆動装置
US20050222023A1 (en)	2002-02-07	2005-10-06	Hans-Peter Hauser	Albumin-fused kunitz domain peptides
KR20110014661A (ko)	2002-02-07	2011-02-11	노보자임스 바이오파마 디케이 에이/에스	알부민-융합 쿠니츠 도메인 펩타이드
AU2003231865A1 (en)	2002-05-31	2003-12-19	Genzyme Corporation	Alpha acyloxyacetamides for kallikrein and urokinase inhibition
CA2488558C (en)	2002-06-07	2013-08-20	Dyax Corp.	Prevention and reduction of blood loss
US7153829B2 (en) *	2002-06-07	2006-12-26	Dyax Corp.	Kallikrein-inhibitor therapies
RU2296769C2 (ru)	2002-07-24	2007-04-10	Ф.Хоффманн-Ля Рош Аг	Пэгилированный полипептид т20
WO2004012773A1 (en)	2002-07-24	2004-02-12	F. Hoffmann-La Roche Ag	Polyalkylene glycol acid additives
ES2709103T3 (es)	2002-08-28	2019-04-15	Dyax Corp	Métodos para conservar órganos y tejidos
US8129330B2 (en)	2002-09-30	2012-03-06	Mountain View Pharmaceuticals, Inc.	Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US20040062748A1 (en)	2002-09-30	2004-04-01	Mountain View Pharmaceuticals, Inc.	Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US7314613B2 (en)	2002-11-18	2008-01-01	Maxygen, Inc.	Interferon-alpha polypeptides and conjugates
RS20050502A (sr)	2002-12-26	2007-08-03	Mountain View Pharmaceuticals Inc.,	Polimerni konjugati interferona- beta sa povećanom biološkom aktivnošću
WO2004063337A2 (en)	2003-01-07	2004-07-29	Dyax Corporation	Kunitz domain library
EP1599222B1 (de)	2003-01-08	2009-03-04	Novartis Vaccines and Diagnostics, Inc.	Stabilisierte wässrige zusammensetzungen mit gewebefaktorinhibitor (tfpi) oder gewebefaktorinhibitor-variante
EP1589949B1 (de)	2003-01-08	2008-08-13	Novartis Vaccines and Diagnostics, Inc.	Stabilisierte lyophilisierte zubereitungen mit gewebefaktor-inhibitor (tfpi) oder varianten des gewebefaktor-inhibitors
DE10301300B4 (de)	2003-01-15	2009-07-16	Curacyte Chemistry Gmbh	Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein
US6989369B2 (en) *	2003-02-07	2006-01-24	Dyax Corp.	Kunitz domain peptides
US20060205671A1 (en)	2003-07-02	2006-09-14	Jakob Vinten-Johansen	Compositions and methods for use of a protease inhibitor and adenosine for preventing organ ischemia and reperfusion injury
JP2007528721A (ja)	2003-08-14	2007-10-18	ダイアックスコーポレイション	エンドセリアーゼ−２リガンド
DK1663281T3 (en)	2003-08-29	2014-03-17	Dyax Corp	POLY-PEGYLED PROTEASE INHIBITORS
EP1663279A4 (de)	2003-08-29	2009-02-18	Dyax Corp	Modifizierte proteasehemmer
US8114123B2 (en)	2003-09-19	2012-02-14	St. Jude Medical, Inc.	Apparatus and methods for tissue gathering and securing
WO2005032556A1 (en)	2003-10-02	2005-04-14	Elan Pharmaceuticals, Inc.	Method for reducing pain
US20060228331A1 (en)	2003-10-10	2006-10-12	Novo Nordisk A/S	IL-21 Derivatives and variants
WO2005041631A2 (en)	2003-10-21	2005-05-12	Dyax Corp.	Endotheliase-1 ligands
EP1713929A2 (de)	2004-02-03	2006-10-25	Bayer HealthCare AG	Diagnostika und therapeutika für mit plasma-kallikrein (klkb1) assoziierten krankheiten
WO2005095327A1 (ja)	2004-03-31	2005-10-13	Ajinomoto Co., Inc.	アニリン誘導体
AU2005271523B2 (en)	2004-08-03	2011-09-15	Dyax Corp.	hk1-binding proteins
US7235530B2 (en) *	2004-09-27	2007-06-26	Dyax Corporation	Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
WO2006057997A2 (en)	2004-11-22	2006-06-01	Dyax Corp.	Plasmin-inhibitory therapies
ITMI20042442A1 (it)	2004-12-21	2005-03-21	Aliveris S R L	Paste alimentari con migliorate caratteristiche di digeribilita'
JP5118492B2 (ja)	2004-12-23	2013-01-16	ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー	血栓の形成の防止および／または安定化の防止
US20060183771A1 (en)	2005-02-17	2006-08-17	Seiffert Dietmar A	Novel combination of selective factor VIIa and/or factor XIa inhibitors and selective plasma kallikrein inhibitors
US8841259B2 (en)	2005-02-24	2014-09-23	Joslin Diabetes Center	Compositions and methods for treating vascular permeability
SI1877435T2 (sl)	2005-05-04	2021-05-31	Zealand Pharma A/S	Analogi glukagonu podobnega peptida-2(GLP-2)
US7583040B2 (en)	2005-09-30	2009-09-01	9141-0720 Quebec Inc.	Motorized closure operating device with electronic control system
US20070079096A1 (en)	2005-09-30	2007-04-05	Chih-Wei Chen	Data storage unit access authorization table automatic rebuilding method and system
PT1981519T (pt)	2005-12-29	2018-02-23	Dyax Corp	Inibição de protéases
US7276480B1 (en) *	2005-12-30	2007-10-02	Dyax Corp.	Prevention and reduction of blood loss
CA2643693A1 (en) *	2006-03-10	2007-09-20	Dyax Corp.	Formulations for ecallantide
HUE039108T2 (hu)	2006-03-16	2018-12-28	Dyax Corp	Készítmények és eljárások szembetegségek kezelésére
US20080031426A1 (en)	2006-06-27	2008-02-07	Weeks Walter L	Audio, video, and navigational law enforcement system and method
EP1873344A1 (de)	2006-06-30	2008-01-02	Sika Technology AG	Mittels Silikon agedichtete Verklebung
AU2007281220B2 (en)	2006-07-31	2013-08-15	Activesite Pharmaceuticals, Inc.	Inhibitors of plasma kallikrein
US20080299050A1 (en)	2006-10-05	2008-12-04	Drugtech Corporation	Topical therapies for oral mucositis and other conditions
EP2195010A4 (de)	2007-08-21	2012-03-14	Genzyme Corp	Behandlung mit kallikrein-inhibitoren
CA2695012A1 (en)	2007-08-23	2009-02-26	Genzyme Corporation	Treatment with kallikrein inhibitors
WO2009102927A1 (en)	2008-02-13	2009-08-20	Dyax Corp.	Improved methods for producing specific binding pairs
DE102008027574A1 (de)	2008-06-10	2009-12-17	Merck Patent Gmbh	Neue Pyrrolidinderivate als MetAP-2 Inhibitoren
DE102008033095A1 (de)	2008-07-15	2010-01-28	Uhde Gmbh	Vorrichtung zur Schlackeabführung aus einem Kohlevergasungsreaktor
US8637454B2 (en)	2009-01-06	2014-01-28	Dyax Corp.	Treatment of mucositis with kallikrein inhibitors
RS62853B1 (sr)	2010-01-06	2022-02-28	Takeda Pharmaceuticals Co	Proteini koji vezuju kalikrein plazme
AU2012204202A1 (en)	2011-01-06	2013-07-11	Dyax Corp.	Plasma kallikrein binding proteins
US8691861B2 (en)	2011-04-13	2014-04-08	Activesite Pharmaceuticals, Inc.	Prodrugs of inhibitors of plasma kallikrein
HRP20190528T1 (hr)	2013-01-20	2019-05-17	Dyax Corp.	PROCJENA, TESTOVI I LIJEČENJE POREMEĆAJA POSREDOVANIH S pKAL
AU2015235967B2 (en)	2014-03-27	2020-10-22	Takeda Pharmaceutical Company Limited	Compositions and methods for treatment of diabetic macular edema

2003
- 2003-06-06 CA CA2488558A patent/CA2488558C/en not_active Expired - Lifetime
- 2003-06-06 DK DK07023364.8T patent/DK1941867T3/da active
- 2003-06-06 WO PCT/US2003/017665 patent/WO2003103475A2/en not_active Ceased
- 2003-06-06 PT PT03757339T patent/PT1531791E/pt unknown
- 2003-06-06 EP EP03757339A patent/EP1531791B1/de not_active Expired - Lifetime
- 2003-06-06 PT PT101804847T patent/PT2311432E/pt unknown
- 2003-06-06 AU AU2003243394A patent/AU2003243394B2/en not_active Expired
- 2003-06-06 ES ES10180484.7T patent/ES2528254T3/es not_active Expired - Lifetime
- 2003-06-06 DK DK03757339.1T patent/DK1531791T3/da active
- 2003-06-06 EP EP10180484.7A patent/EP2311432B1/de not_active Expired - Lifetime
- 2003-06-06 ES ES07023364T patent/ES2372978T3/es not_active Expired - Lifetime
- 2003-06-06 US US10/456,986 patent/US7064107B2/en not_active Expired - Lifetime
- 2003-06-06 DK DK10180486.2T patent/DK2298278T3/en active
- 2003-06-06 AT AT07023364T patent/ATE528014T1/de active
- 2003-06-06 EP EP10180486.2A patent/EP2298278B1/de not_active Expired - Lifetime
- 2003-06-06 PT PT101804862T patent/PT2298278E/pt unknown
- 2003-06-06 PT PT07023364T patent/PT1941867E/pt unknown
- 2003-06-06 DE DE60333758T patent/DE60333758D1/de not_active Expired - Lifetime
- 2003-06-06 DK DK10180484.7T patent/DK2311432T3/en active
- 2003-06-06 AT AT03757339T patent/ATE477020T1/de active
- 2003-06-06 EP EP07023364A patent/EP1941867B1/de not_active Expired - Lifetime
- 2003-06-06 ES ES10180486.2T patent/ES2559927T3/es not_active Expired - Lifetime
- 2003-06-06 JP JP2004510605A patent/JP2005534647A/ja active Pending
- 2003-06-06 ES ES03757339T patent/ES2348230T3/es not_active Expired - Lifetime
2005
- 2005-12-30 US US11/322,960 patent/US20060194727A1/en not_active Abandoned
2007
- 2007-04-27 US US11/796,272 patent/US20080064637A1/en not_active Abandoned
- 2007-10-30 US US11/930,012 patent/US7811991B2/en not_active Expired - Lifetime
- 2007-10-30 US US11/930,018 patent/US20080131426A1/en not_active Abandoned
- 2007-10-30 US US11/929,729 patent/US8124586B2/en not_active Expired - Lifetime
- 2007-10-31 US US11/931,373 patent/US7851442B2/en not_active Expired - Lifetime
- 2007-10-31 US US11/931,635 patent/US20080152656A1/en not_active Abandoned
- 2007-11-02 US US11/934,181 patent/US20080260752A1/en not_active Abandoned
2008
- 2008-05-29 AU AU2008202377A patent/AU2008202377B2/en not_active Expired
2010
- 2010-01-12 JP JP2010004265A patent/JP5249251B2/ja not_active Expired - Lifetime
- 2010-11-22 US US12/951,543 patent/US8710007B2/en not_active Expired - Lifetime
2011
- 2011-04-20 AU AU2011201811A patent/AU2011201811A1/en not_active Abandoned
2012
- 2012-01-11 CY CY20121100027T patent/CY1112228T1/el unknown
- 2012-11-01 JP JP2012242083A patent/JP2013049698A/ja active Pending
2014
- 2014-04-28 US US14/263,764 patent/US9480733B2/en not_active Expired - Lifetime
2016
- 2016-06-07 US US15/175,644 patent/US10245307B2/en not_active Expired - Lifetime
2019
- 2019-02-21 US US16/281,276 patent/US11344610B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
US9480733B2 (en)	2016-11-01
JP2010155842A (ja)	2010-07-15
US20040038893A1 (en)	2004-02-26
EP2311432B1 (de)	2014-12-24
PT2311432E (pt)	2015-02-09
DK2298278T3 (en)	2016-02-01
WO2003103475A2 (en)	2003-12-18
US8710007B2 (en)	2014-04-29
US20080200646A1 (en)	2008-08-21
AU2003243394B2 (en)	2008-06-12
US20110086801A1 (en)	2011-04-14
EP1941867B1 (de)	2011-10-12
JP2005534647A (ja)	2005-11-17
AU2008202377A1 (en)	2008-06-19
US20090082267A1 (en)	2009-03-26
EP2298278B1 (de)	2015-11-11
EP1531791A2 (de)	2005-05-25
ATE477020T1 (de)	2010-08-15
US20080152656A1 (en)	2008-06-26
AU2003243394A1 (en)	2003-12-22
EP2311432A1 (de)	2011-04-20
US10245307B2 (en)	2019-04-02
ES2559927T3 (es)	2016-02-16
US8124586B2 (en)	2012-02-28
PT2298278E (pt)	2016-02-25
ES2372978T3 (es)	2012-01-30
US20080064637A1 (en)	2008-03-13
EP1941867A1 (de)	2008-07-09
US20160361395A1 (en)	2016-12-15
US20140349940A1 (en)	2014-11-27
AU2011201811A1 (en)	2011-05-19
US7064107B2 (en)	2006-06-20
DK2311432T3 (en)	2015-02-02
US20080260752A1 (en)	2008-10-23
US20190247477A1 (en)	2019-08-15
EP1531791B1 (de)	2010-08-11
US20080131426A1 (en)	2008-06-05
US7811991B2 (en)	2010-10-12
DK1941867T3 (da)	2012-01-02
US20060194727A1 (en)	2006-08-31
ES2528254T3 (es)	2015-02-05
CY1112228T1 (el)	2015-12-09
JP5249251B2 (ja)	2013-07-31
DE60333758D1 (de)	2010-09-23
HK1119955A1 (en)	2009-03-20
JP2013049698A (ja)	2013-03-14
PT1531791E (pt)	2010-12-16
EP1531791A4 (de)	2008-05-21
ES2348230T3 (es)	2010-12-01
US11344610B2 (en)	2022-05-31
CA2488558C (en)	2013-08-20
WO2003103475A3 (en)	2005-03-10
CA2488558A1 (en)	2003-12-18
EP2298278A1 (de)	2011-03-23
US7851442B2 (en)	2010-12-14
HK1154513A1 (en)	2012-04-27
PT1941867E (pt)	2012-02-16
AU2008202377B2 (en)	2011-05-12
DK1531791T3 (da)	2010-11-01
HK1154211A1 (en)	2012-04-13
US20080076712A1 (en)	2008-03-27

Legal Events

Date

Code

Title

Description

2012-04-15

UEP

Publication of translation of european patent specification

Ref document number: 1941867

Country of ref document: EP

Publication	Publication Date	Title
ATE528014T1 (de)	2011-10-15	Polypeptid mit modifizierten kunitz domains
NO942553D0 (no)	1994-07-06	Ny humanproteaseinhibitor av Kunitz-type og varianter derav
DE69942035D1 (de)	2010-04-01	Menschliches parathyroidhormon, modifikationen, herstellung und verwendung
NL300013I1 (nl)	2000-10-02	Nieuwe protein met TNF-remmende werking en hun ber
DE69128664D1 (de)	1998-02-19	CNP-Gen und Vorläuferprotein aus Schwein
WO2001005810A3 (de)	2001-05-17	CYCLISCHE PEPTIDDERIVATE ALS INHIBITOREN DES INTEGRINS αvβ¿6?
DK1519951T3 (da)	2007-09-24	Kationiske ligekædede peptider med antifungale egenskaber
DE3751398D1 (de)	1995-08-17	Substrat-Peptide.
HUP9702500A2 (hu)	1998-07-28	Elhízás elleni proteinek
ES2171157T3 (es)	2002-09-01	Gen recombinante codificante para una proteina con actividad endoquitinasa.
CY1115911T1 (el)	2017-01-25	Τροποποιημενα πολυπεπτιδια περιοχης kunitz και η χρηση τους στην μειωση της ισχαιμιας ή της εκκινησης μιας συστημικης φλεγμονωδους ανταποκρισης που σχετιζεται με μια χειρουργικη επεμβαση
ATE388965T1 (de)	2008-03-15	Menschliche antithrombin-varianten
FR2787454B1 (fr)	2002-02-15	Inhibiteur de la topoisomerase ii
ATE432985T1 (de)	2009-06-15	Polypeptide mit aktivität der stimulierung von neutrophilen
CO4340568A1 (es)	1996-07-30	Familia de peptidos con 51 aminoacidos en longitud, secuen- cias de definicion, la planta transgenica comprendida, el vector de expresion recombinante y el metodo para su pro- duccion.